CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Updates on Joint Venture
As per the attached letter.05-05-2021
05-05-2021
CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
As per the attached letter01-05-2021
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
As per the attached letter30-04-2021
Cadila Healthcare Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate26-04-2021
Movers and Shakers: Stocks that will see action this week
Cadila Healthcare (570.9)Hits new all-time highThe stock of Cadila Healthcare, which had been moving down gradually since the beginning of the year,25-04-2021
Movers and Shakers: Stocks that will see action this week
Cadila Healthcare (570.9)Hits new all-time highThe stock of Cadila Healthcare, which had been moving down gradually since the beginning of the year,24-04-2021
Cadila Healthcare's Hepatitis C drug gets approval for emergency use
Approval from the drug regulator follows late-stage study of the medicine23-04-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives Emergency Use Approval from DCGI for the use of Pegylated Interferon alpha-2b, 'Virafin' in treating moderate COVID-19 infection in adults23-04-2021
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives final approval from USFDA for Propafenone Hydrochloride Extended-Release Capsules23-04-2021
Cadila looks to double Covid-19 vaccine capacity amid record India surge
Cadila is expecting efficacy readings from its last stage of clinical trials in May, Sharvil Patel, managing director, said in an interview.20-04-2021